{
    "nct_id": "NCT03603002",
    "official_title": "Studying the Pathologic and Immunologic Response After Ablative Radiation in Stage I Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations\n* Age > 18 year\n* Confirmed non-small cell lung cancer after initial biopsies\n* Patient with accessible tumor for biopsy\n* Patient is to have sufficient initial core biopsy samples for tissue analyses\n* Stage I lung cancer\n* Adequate normal organ and marrow function\n* Patient with tumor amenable to SABR treatment as determined by a radiation oncologist\n* Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* Post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Primary tumors not amenable to serial core biopsies.\n* Prior thoracic radiation in the region that will be treated by SABR.\n* Patient may not be receiving any other concurrent investigational agents or chemotherapy.\n* Patient may not be receiving or received immunotherapy.\n* Patients may not be on or use steroids within 14 days before radiation, and from the duration of radiation to the time of the post-SABR biopsies and blood samples.\n* Female patients who are pregnant from screening to completion of SABR",
    "miscellaneous_criteria": ""
}